MyNorthwest

News

Opinion

Sports

Tools

Connect

Probe: Alzheimer’s drug approval ‘rife with irregularities’

FILE - A sign for the Food and Drug Administration is displayed outside their offices in Silver Spring, Md., on Dec. 10, 2020. The FDA’s contentious approval of a questionable Alzheimer’s drug took another hit Thursday, Dec. 29, 2022, as congressional investigators called the process “rife with irregularities.” (AP Photo/Manuel Balce Ceneta, File)

FILE - This image provided by Biogen on Monday, June 7, 2021 shows a vial and packaging for the drug Aduhelm. The Food and Drug Administration’s contentious approval of a questionable Alzheimer’s drug took another hit Thursday, Dec. 29, 2022, as congressional investigators called the process “rife with irregularities.” (Biogen via AP, File)

Probe: Alzheimer’s drug approval ‘rife with irregularities’